New research links PSA and PSA density to long-term prostate cancer risk, supporting risk-adapted screening strategies. Learn more about the 20-year findings.

It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...

PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...

Researchers assess the adequacy of tissue ablation by a cooled laser therapy in patients with localized prostate cancer.

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ...

A prostate-specific antigen (PSA) test is a blood test that measures a protein released in the blood by prostate cells. Both normal and cancerous prostate cells release the protein. Most of the time, ...

Many men with low levels could be spared from invasive procedures and frequent testing ...

CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...

Prostate cancer highlights from the American Urological Association 2025 meeting include quality-of-life results from the phase 3 PSMAfore study, findings on androgen deprivation therapy (ADT) with or ...